The invention relates to a nicotinic 
acid derivative shown in the formula (I), and pharmaceutically acceptable salt or solvate thereof, wherein Z is selected from O, S and NR3, and R3 is 
hydrogen or C1-6 
alkyl; R1 or R2 is independently selected from 
hydrogen, C1-6 
alkyl, C1-6 
alkoxy group, halogenated C1-6 
alkyl, 
halogen, nitro, 
aryl, 
aryl oxygroup, heteroaryl, heteroaryl oxygroup, heterocyclic radical, and heterocyclic oxygroup; C1-6 
alkoxy group, halogenated C1-6 alkyl, 
aryl, heteroaryl, and heterocyclic radical can be optionally substituted by 
substituent groups which can be C1-6 alkyl, C1-6 
alkoxy group, halogenated C1-6 alkyl, 
halogen, cycano, nitro and aryl; m is an integer of 0 to 4; and n is an integer of 0 to 5. The compound or salts thereof have strong inhibition activity to 
colorectal cancer cell line HCT-116, 
human lung cancer cell line A549 and 
breast cancer cell line MCF-7. In addition, the compound is broad-spectrum in anti-
cancer activity, and can be used as a candidate 
drug or a 
pilot compound for treating diseases of tumors, cancers and the like.